Brief: Cyclopharm Posts FY Sales Revenue Of A$17.70 Million
23/02/2022 09:57
Feb 23 (Reuters) - Cyclopharm:
* FY SALES REVENUE OF A$17.70 MILLION, UP 20.6%
* FINAL DIVIDEND MAINTAINED AT 0.5 AU CENTS PER SHARE
* REVENUE FROM TECHNEGAS GENERATOR & PAS SALES IS EXPECTED
TO
CONTINUE TO REBOUND TO PRE‐PANDEMIC LEVELS OR BEYOND IN 2022
Source text for Eikon: ID:nASXbxmy01
Further company coverage: CYC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclopharm
See all newsAustralia's Cyclopharm rises after Chinese medical groups back its Technegas
Australia's Cyclopharm gains most in 8-months on Technegas rollout deal
Australia's Cyclopharm rises on HY revenue forecast
Brief: Cyclopharm Forecasts 1H Global Revenue Of A$17.1 Million
Brief: Cyclopharm Says David Heaney To Retire As Non-Executive Chair